AI Article Synopsis

  • Primary cutaneous diffuse large B-cell lymphoma (DLBCL) is a rare type of lymphoma observed primarily in elderly patients, with a higher incidence in men.
  • Cases were analyzed using specific antibodies and genetic tests to understand the characteristics better.
  • Among patients with lesions on the lower extremities, recurrence rates were 50%, compared to 18% for lesions in other areas, highlighting a potential difference in outcomes based on tumor location.

Article Abstract

Primary cutaneous diffuse large B-cell lymphoma (DLBCL) is an uncommon lymphoma. Some authors have suggested that large B-cell lymphoma can be segregated based on anatomic site, with tumors of the lower extremity being unique. We report 15 cases of primary cutaneous DLBCL. Each case was analyzed immunohistochemically using antibodies specific for CD3, CD5, CD10, CD20, bcl-2, bcl-6, and p53. Polymerase chain reaction analysis for t(14;18)(q32;q21) also was performed. There were 13 men and 2 women (median age, 64 years). Thirteen tumors were composed predominantly of centroblasts, and 2 were immunoblastic. There was a median follow-up of 72 months. Of the 4 patients with primary cutaneous DLBCL of the lower extremity (thigh, knee, leg), 2 (50%) experienced a recurrence and 1 patient died of disease. In the non-lower extremity cases, 18% (2/11) recurred and no patients died of disease. We conclude that primary cutaneous DLBCL usually occurs in elderly patients with a male predominance. Recurrences are common, but death of disease is rare.

Download full-text PDF

Source
http://dx.doi.org/10.1309/edal-r8ha-u3el-t37dDOI Listing

Publication Analysis

Top Keywords

primary cutaneous
20
large b-cell
12
b-cell lymphoma
12
cutaneous dlbcl
12
cutaneous diffuse
8
diffuse large
8
cases primary
8
lower extremity
8
died disease
8
primary
5

Similar Publications

Background: Locally advanced periorbital cutaneous squamous cell carcinoma (cSCC) may require orbital exenteration, which is highly morbid. As immunotherapy develops, orbit preservation may become widespread, and data benchmarking survival with current standard-of-care surgery and radiotherapy are essential to the integration of this emerging method into modern treatment paradigms. This study aimed to determine the survival of patients after orbital exenteration for cSCC and investigate contributing factors.

View Article and Find Full Text PDF

Dermatofibrosarcoma protuberans (DFSP) is a rare, locally invasive cutaneous sarcoma with a high propensity for recurrence, even following complete surgical excision. DFSP exhibits a low metastatic potential and is characterized by a distinctive honeycomb-like architecture composed of uniformly arranged spindle cells that frequently show CD34 immunostaining. Common surgical approaches include wide local excision (WLE), Mohs micrographic surgery (MMS), and, in severe cases, amputation.

View Article and Find Full Text PDF

Background: Skin problems, typically overlooked in elderly patients hospitalized for systemic diseases, can no longer be ignored.

Objectives:  This study aimed to investigate the presence and management of dermatological problems in hospitalized elderly patients.

Materials And Methods: This retrospective study involved dermatology consultations for 712 elderly patients (aged ≥ 65 years) hospitalized between October 2022 and October 2023.

View Article and Find Full Text PDF

Objective: To evaluate the relation between solar elastosis and tumor mutation burden (TMB) in a large clinically annotated cohort of stage II and III melanoma patients.

Methods: Primary cutaneous melanomas from 469 AJCC (8 edition) stage II and III patients with clinical annotation including outcome at 5 years of diagnosis were histopathologically evaluated for solar elastosis. Next-generation sequencing assay MSK-IMPACT was employed to determine TMB.

View Article and Find Full Text PDF

Background: Dermatomyositis is a chronic autoimmune disease with distinctive cutaneous eruptions and muscle weakness, and the pathophysiology is characterised by type I interferon (IFN) dysregulation. This study aims to assess the efficacy, safety, and target engagement of dazukibart, a potent, selective, humanised IgG1 neutralising monoclonal antibody directed against IFNβ, in adults with moderate-to-severe dermatomyositis.

Methods: This multicentre, double-blind, randomised, placebo-controlled, phase 2 trial was conducted at 25 university-based hospitals and outpatient sites in Germany, Hungary, Poland, Spain, and the USA.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!